卖什么
Population health analytics powered by wastewater.
商业模式拆解
买家：谁掌握预算？
未核实Public health agency leaders (federal biodefense, state/local health departments) and pharma commercial/clinical development teams.
触发点：什么让他们现在购买？
Need earlier outbreak and substance-use signals than clinical reports (e.g. measles, H5N1, fentanyl); pharma needing faster trial recruitment and campaign timing.
工作流：什么输入变成什么输出？
Biobot provides sampling kits, logistics, lab analysis and data dashboards; wastewater is tested for 50+ pathogens and substances, and predictive data feeds into outbreak response, trial recruitment, marketing/DSP targeting.
经济账：省了什么，怎么收费？
Data/analytics subscriptions to government and pharma; pharma claims a two-week commercial head start; funded in part by SBIR Phase I-III awards.
渠道：怎么接触到客户？
Demo-led sales (Book a Demo) segmented by government, pharma and treatment plants; partnerships with CDC's National Wastewater Surveillance System.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2018 冬季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.